Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.

Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GL, Allan JM.

Blood Adv. 2018 May 22;2(10):1157-1169. doi: 10.1182/bloodadvances.2017015214.

2.

Epidemiology and biology of relapse after stem cell transplantation.

Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, Vago L, Kröger N.

Bone Marrow Transplant. 2018 Apr 18. doi: 10.1038/s41409-018-0171-z. [Epub ahead of print] Review. No abstract available.

PMID:
29670211
3.

Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.

Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ.

Haematologica. 2018 Apr;103(4):634-644. doi: 10.3324/haematol.2017.172304. Epub 2018 Feb 15.

4.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

5.

The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.

Garrido Castro P, van Roon EHJ, Pinhanços SS, Trentin L, Schneider P, Kerstjens M, Te Kronnie G, Heidenreich O, Pieters R, Stam RW.

Leukemia. 2018 Feb;32(2):323-331. doi: 10.1038/leu.2017.216. Epub 2017 Jul 10.

PMID:
28690313
6.

RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.

Loke J, Assi SA, Imperato MR, Ptasinska A, Cauchy P, Grabovska Y, Soria NM, Raghavan M, Delwel HR, Cockerill PN, Heidenreich O, Bonifer C.

Cell Rep. 2017 May 23;19(8):1654-1668. doi: 10.1016/j.celrep.2017.05.005.

7.

Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.

Elder A, Bomken S, Wilson I, Blair HJ, Cockell S, Ponthan F, Dormon K, Pal D, Heidenreich O, Vormoor J.

Leukemia. 2017 Dec;31(12):2577-2586. doi: 10.1038/leu.2017.140. Epub 2017 May 10.

8.

MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.

Kerry J, Godfrey L, Repapi E, Tapia M, Blackledge NP, Ma H, Ballabio E, O'Byrne S, Ponthan F, Heidenreich O, Roy A, Roberts I, Konopleva M, Klose RJ, Geng H, Milne TA.

Cell Rep. 2017 Jan 10;18(2):482-495. doi: 10.1016/j.celrep.2016.12.054.

9.

Dormancy Stems the Tide of Chemotherapy.

Pal D, Heidenreich O, Vormoor J.

Cancer Cell. 2016 Dec 12;30(6):825-826. doi: 10.1016/j.ccell.2016.11.014.

10.

Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia.

Pal D, Blair HJ, Elder A, Dormon K, Rennie KJ, Coleman DJ, Weiland J, Rankin KS, Filby A, Heidenreich O, Vormoor J.

Leukemia. 2016 Aug;30(8):1691-700. doi: 10.1038/leu.2016.79. Epub 2016 May 25.

11.

BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance.

Weiland J, Pal D, Case M, Irving J, Ponthan F, Koschmieder S, Heidenreich O, von Stackelberg A, Eckert C, Vormoor J, Elder A.

Leukemia. 2016 Sep;30(9):1920-3. doi: 10.1038/leu.2016.64. Epub 2016 Mar 17. No abstract available.

12.

The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.

Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C.

Blood. 2016 Apr 21;127(16):1998-2006. doi: 10.1182/blood-2015-08-665034. Epub 2016 Feb 11.

13.

UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.

Goyama S, Schibler J, Gasilina A, Shrestha M, Lin S, Link KA, Chen J, Whitman SP, Bloomfield CD, Nicolet D, Assi SA, Ptasinska A, Heidenreich O, Bonifer C, Kitamura T, Nassar NN, Mulloy JC.

Leukemia. 2016 Mar;30(3):728-39. doi: 10.1038/leu.2015.275. Epub 2015 Oct 9.

14.

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.

Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ, Bornhauser B, Gombert M, Kratsch C, Stütz AM, Sultan M, Tchinda J, Worth CL, Amstislavskiy V, Badarinarayan N, Baruchel A, Bartram T, Basso G, Canpolat C, Cario G, Cavé H, Dakaj D, Delorenzi M, Dobay MP, Eckert C, Ellinghaus E, Eugster S, Frismantas V, Ginzel S, Haas OA, Heidenreich O, Hemmrich-Stanisak G, Hezaveh K, Höll JI, Hornhardt S, Husemann P, Kachroo P, Kratz CP, Te Kronnie G, Marovca B, Niggli F, McHardy AC, Moorman AV, Panzer-Grümayer R, Petersen BS, Raeder B, Ralser M, Rosenstiel P, Schäfer D, Schrappe M, Schreiber S, Schütte M, Stade B, Thiele R, von der Weid N, Vora A, Zaliova M, Zhang L, Zichner T, Zimmermann M, Lehrach H, Borkhardt A, Bourquin JP, Franke A, Korbel JO, Stanulla M, Yaspo ML.

Nat Genet. 2015 Sep;47(9):1020-1029. doi: 10.1038/ng.3362. Epub 2015 Jul 27.

15.

Gene Silencing by RNAi in Mammalian Cells.

Ponthan F, Yusoff NM, Soria NM, Heidenreich O, Coffey K.

Curr Protoc Mol Biol. 2015 Jul 1;111:26.2.1-17. doi: 10.1002/0471142727.mb2602s111.

PMID:
26131850
16.

The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype.

Forster VJ, Nahari MH, Martinez-Soria N, Bradburn AK, Ptasinska A, Assi SA, Fordham SE, McNeil H, Bonifer C, Heidenreich O, Allan JM.

Leukemia. 2016 Jan;30(1):250-3. doi: 10.1038/leu.2015.133. Epub 2015 Jun 8. No abstract available.

17.

The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

Eswaran J, Sinclair P, Heidenreich O, Irving J, Russell LJ, Hall A, Calado DP, Harrison CJ, Vormoor J.

Leukemia. 2015 Aug;29(8):1623-31. doi: 10.1038/leu.2015.113. Epub 2015 May 6. Review.

PMID:
25943180
18.

CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.

Weiland J, Elder A, Forster V, Heidenreich O, Koschmieder S, Vormoor J.

Pediatr Blood Cancer. 2015 Jul;62(7):1144-8. doi: 10.1002/pbc.25462. Epub 2015 Mar 8. Review.

PMID:
25755168
19.

Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal.

Ptasinska A, Assi SA, Martinez-Soria N, Imperato MR, Piper J, Cauchy P, Pickin A, James SR, Hoogenkamp M, Williamson D, Wu M, Tenen DG, Ott S, Westhead DR, Cockerill PN, Heidenreich O, Bonifer C.

Cell Rep. 2014 Sep 25;8(6):1974-1988. doi: 10.1016/j.celrep.2014.08.024. Epub 2014 Sep 18.

20.

Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.

Vormoor B, Knizia HK, Batey MA, Almeida GS, Wilson I, Dildey P, Sharma A, Blair H, Hide IG, Heidenreich O, Vormoor J, Maxwell RJ, Bacon CM.

PLoS One. 2014 Jan 7;9(1):e85128. doi: 10.1371/journal.pone.0085128. eCollection 2014.

21.

Pontin is a critical regulator for AML1-ETO-induced leukemia.

Breig O, Bras S, Martinez Soria N, Osman D, Heidenreich O, Haenlin M, Waltzer L.

Leukemia. 2014 Jun;28(6):1271-9. doi: 10.1038/leu.2013.376. Epub 2013 Dec 17.

PMID:
24342949
22.

Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.

Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair HJ, Vormoor J, Ottmann O, Ganser A, Pich A, Hilfiker-Kleiner D, Heidenreich O, Eder M.

Leukemia. 2014 Mar;28(3):554-65. doi: 10.1038/leu.2013.361. Epub 2013 Nov 27.

23.

Determination of key structure-activity relationships in siRNA delivery with a mixed micelle system.

Omedes Pujol M, Coleman DJ, Allen CD, Heidenreich O, Fulton DA.

J Control Release. 2013 Dec 28;172(3):939-45. doi: 10.1016/j.jconrel.2013.10.013. Epub 2013 Oct 18.

24.

The MLL recombinome of acute leukemias in 2013.

Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer BW, Kubetzko S, Alonso CN, zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R.

Leukemia. 2013 Nov;27(11):2165-76. doi: 10.1038/leu.2013.135. Epub 2013 Apr 30.

25.

Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression.

Ray D, Kwon SY, Tagoh H, Heidenreich O, Ptasinska A, Bonifer C.

Blood. 2013 Aug 1;122(5):759-69. doi: 10.1182/blood-2013-02-482497. Epub 2013 Apr 24.

26.

Molecular parameters of siRNA--cell penetrating peptide nanocomplexes for efficient cellular delivery.

van Asbeck AH, Beyerle A, McNeill H, Bovee-Geurts PH, Lindberg S, Verdurmen WP, Hällbrink M, Langel U, Heidenreich O, Brock R.

ACS Nano. 2013 May 28;7(5):3797-807. doi: 10.1021/nn305754c. Epub 2013 Apr 30.

PMID:
23600610
27.

Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations.

Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, Stanulla M, Schrappe M, Hall AG, Heidenreich O, Vormoor J.

EMBO Mol Med. 2013 Jan;5(1):38-51. doi: 10.1002/emmm.201201703. Epub 2012 Dec 11.

28.

Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression.

Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H, Bacon CM, Vormoor J, Heidenreich O.

Leukemia. 2013 Mar;27(3):718-21. doi: 10.1038/leu.2012.206. Epub 2012 Jul 18. No abstract available. Erratum in: Leukemia. 2013 Aug;27(8):1792.

29.

Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.

Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C.

Leukemia. 2012 Aug;26(8):1829-41. doi: 10.1038/leu.2012.49. Epub 2012 Feb 20.

30.

AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia.

Dunne J, Mannari D, Farzaneh T, Gessner A, van Delft FW, Heidenreich O, Young BD, Gascoyne DM.

Leukemia. 2012 May;26(5):1131-5. doi: 10.1038/leu.2011.316. Epub 2011 Nov 8. No abstract available.

PMID:
22064348
31.

[Effective and specific control of aml1/eto gene expression in acute myeloid leukemia cells by lentivecior-based RNA-interference].

Grinev VV, Posrednik DV, Heidenreich O.

Mol Biol (Mosk). 2011 Mar-Apr;45(2):335-45. Russian.

PMID:
21634121
32.

The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.

Duque-Afonso J, Yalcin A, Berg T, Abdelkarim M, Heidenreich O, Lübbert M.

Oncogene. 2011 Jul 7;30(27):3062-72. doi: 10.1038/onc.2011.32. Epub 2011 May 16.

PMID:
21577204
33.

Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.

Gessner A, Thomas M, Castro PG, Büchler L, Scholz A, Brümmendorf TH, Soria NM, Vormoor J, Greil J, Heidenreich O.

Leukemia. 2010 Oct;24(10):1751-9. doi: 10.1038/leu.2010.155. Epub 2010 Aug 5.

PMID:
20686504
34.

Understanding the cancer stem cell.

Bomken S, Fiser K, Heidenreich O, Vormoor J.

Br J Cancer. 2010 Aug 10;103(4):439-45. doi: 10.1038/sj.bjc.6605821. Epub 2010 Jul 27. Review.

35.

AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.

Dunne J, Gascoyne DM, Lister TA, Brady HJ, Heidenreich O, Young BD.

Cancer Res. 2010 May 15;70(10):3985-95. doi: 10.1158/0008-5472.CAN-09-3604. Epub 2010 May 11.

36.

Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems.

Rothdiener M, Müller D, Castro PG, Scholz A, Schwemmlein M, Fey G, Heidenreich O, Kontermann RE.

J Control Release. 2010 Jun 1;144(2):251-8. doi: 10.1016/j.jconrel.2010.02.020. Epub 2010 Feb 22.

PMID:
20184933
37.

Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6.

Farra R, Dapas B, Pozzato G, Giansante C, Heidenreich O, Uxa L, Zennaro C, Guarnieri G, Grassi G.

Biochimie. 2010 May;92(5):455-63. doi: 10.1016/j.biochi.2010.01.007. Epub 2010 Feb 6.

PMID:
20144681
38.

Proliferation of human primary vascular smooth muscle cells depends on serum response factor.

Werth D, Grassi G, Konjer N, Dapas B, Farra R, Giansante C, Kandolf R, Guarnieri G, Nordheim A, Heidenreich O.

Eur J Cell Biol. 2010 Feb-Mar;89(2-3):216-24. doi: 10.1016/j.ejcb.2009.12.002. Epub 2010 Jan 22.

PMID:
20096952
39.

EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation.

Seizer P, Schönberger T, Schött M, Lang MR, Langer HF, Bigalke B, Krämer BF, Borst O, Daub K, Heidenreich O, Schmidt R, Lindemann S, Herouy Y, Gawaz M, May AE.

Atherosclerosis. 2010 Mar;209(1):51-7. doi: 10.1016/j.atherosclerosis.2009.08.029. Epub 2009 Aug 21.

PMID:
19758589
40.

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving J, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab C, Tönnies H, Dyer MJ, Siebert R, Harrison CJ.

Blood. 2009 Sep 24;114(13):2688-98. doi: 10.1182/blood-2009-03-208397. Epub 2009 Jul 29.

41.

A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO.

Osman D, Gobert V, Ponthan F, Heidenreich O, Haenlin M, Waltzer L.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12043-8. doi: 10.1073/pnas.0902449106. Epub 2009 Jul 6.

42.

Malignant stem cells in childhood ALL: the debate continues!

Heidenreich O, Vormoor J.

Blood. 2009 Apr 30;113(18):4476-7; author reply 4477. doi: 10.1182/blood-2009-02-203109. No abstract available.

43.

Targeting oncogenes with siRNAs.

Heidenreich O.

Methods Mol Biol. 2009;487:221-42. doi: 10.1007/978-1-60327-547-7_11.

PMID:
19301650
44.

New insights to the MLL recombinome of acute leukemias.

Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cavé H, Clappier E, van Dongen JJ, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grümayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C, Möricke A, Schrappe M, Alonso CN, Schäfer BW, Krauter J, Lee DA, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R.

Leukemia. 2009 Aug;23(8):1490-9. doi: 10.1038/leu.2009.33. Epub 2009 Mar 5.

PMID:
19262598
45.

Graft protection in bypass surgery: siRNA-mediated silencing of adhesion molecules.

Walker T, Wendel HP, Raabe C, Wiechnik P, Spranger L, Heidenreich O, Scheule AM, Nordheim A, Ziemer G.

Oligonucleotides. 2009 Mar;19(1):15-21. doi: 10.1089/oli.2008.0148.

PMID:
19125637
46.

A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin.

Russell LJ, De Castro DG, Griffiths M, Telford N, Bernard O, Panzer-Grümayer R, Heidenreich O, Moorman AV, Harrison CJ.

Leukemia. 2009 Mar;23(3):614-7. doi: 10.1038/leu.2008.250. Epub 2008 Sep 25. No abstract available.

PMID:
18818706
47.

Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.

Berg T, Fliegauf M, Burger J, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lübbert M.

Haematologica. 2008 Nov;93(11):1728-33. doi: 10.3324/haematol.13044. Epub 2008 Sep 11.

48.

Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo.

Martinez Soria N, Tussiwand R, Ziegler P, Manz MG, Heidenreich O.

Leukemia. 2009 Jan;23(1):188-90. doi: 10.1038/leu.2008.157. Epub 2008 Jun 12. No abstract available.

PMID:
18548094
49.

Gene silencing by RNAi in mammalian cells.

John M, Geick A, Hadwiger P, Vornlocher HP, Heidenreich O.

Curr Protoc Mol Biol. 2003 May;Chapter 26:Unit 26.2. doi: 10.1002/0471142727.mb2602s62.

PMID:
18265326
50.

Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection.

Walker T, Wendel HP, Tetzloff L, Raabe C, Heidenreich O, Simon P, Scheule AM, Ziemer G.

J Cell Mol Med. 2007 Jan-Feb;11(1):139-47.

Supplemental Content

Loading ...
Support Center